12/5
08:30 am
cgon
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
Medium
Report
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
11/26
07:13 am
cgon
CG Oncology Announces New Board Member and Board Transition [Yahoo! Finance]
Low
Report
CG Oncology Announces New Board Member and Board Transition [Yahoo! Finance]
11/26
07:00 am
cgon
CG Oncology Announces New Board Member and Board Transition
Low
Report
CG Oncology Announces New Board Member and Board Transition
11/25
04:56 pm
cgon
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting [Yahoo! Finance]
Low
Report
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting [Yahoo! Finance]
11/25
04:05 pm
cgon
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
Low
Report
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
11/24
09:04 am
cgon
CG Oncology (NASDAQ:CGON) was given a new $62.00 price target on by analysts at Truist Financial Corporation.
Low
Report
CG Oncology (NASDAQ:CGON) was given a new $62.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
cgon
CG Oncology (NASDAQ:CGON) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
CG Oncology (NASDAQ:CGON) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/18
07:20 am
cgon
CG Oncology (NASDAQ:CGON) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.
Medium
Report
CG Oncology (NASDAQ:CGON) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.
11/17
08:11 am
cgon
CG Oncology (NASDAQ:CGON) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
CG Oncology (NASDAQ:CGON) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
11/15
02:18 pm
cgon
What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders [Yahoo! Finance]
Low
Report
What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders [Yahoo! Finance]
11/14
07:08 pm
cgon
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/14
08:24 am
cgon
CG Oncology GAAP EPS of -$0.57 misses by $0.01, revenue of $1.67M beats by $1.6M [Seeking Alpha]
Low
Report
CG Oncology GAAP EPS of -$0.57 misses by $0.01, revenue of $1.67M beats by $1.6M [Seeking Alpha]
11/14
08:00 am
cgon
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
Medium
Report
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
10/16
04:59 pm
cgon
Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene [Yahoo! Finance]
Low
Report
Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene [Yahoo! Finance]
10/9
08:38 pm
cgon
CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results [Yahoo! Finance]
Medium
Report
CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results [Yahoo! Finance]
10/9
07:15 am
cgon
CG Oncology (NASDAQ:CGON) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Medium
Report
CG Oncology (NASDAQ:CGON) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
10/8
06:50 pm
cgon
Why Cg Oncology Stock Rocketed 7% Higher Today [Yahoo! Finance]
Medium
Report
Why Cg Oncology Stock Rocketed 7% Higher Today [Yahoo! Finance]
10/7
06:04 pm
cgon
CG Oncology (NASDAQ:CGON) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Medium
Report
CG Oncology (NASDAQ:CGON) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
10/4
12:07 am
cgon
9/26
08:05 am
cgon
CG Oncology (NASDAQ:CGON) had its price target raised by analysts at JPMorgan Chase & Co. from $41.00 to $47.00. They now have an "overweight" rating on the stock.
Low
Report
CG Oncology (NASDAQ:CGON) had its price target raised by analysts at JPMorgan Chase & Co. from $41.00 to $47.00. They now have an "overweight" rating on the stock.
9/22
03:23 am
cgon
CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment [Yahoo! Finance]
Low
Report
CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment [Yahoo! Finance]
9/17
02:39 pm
cgon
CG Oncology (NASDAQ:CGON) had its price target raised by analysts at Morgan Stanley from $56.00 to $79.00. They now have an "overweight" rating on the stock.
Low
Report
CG Oncology (NASDAQ:CGON) had its price target raised by analysts at Morgan Stanley from $56.00 to $79.00. They now have an "overweight" rating on the stock.
9/15
08:06 am
cgon
CG Oncology (NASDAQ:CGON) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
CG Oncology (NASDAQ:CGON) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
9/11
06:11 am
cgon
CG Oncology (CGON) Reports Promising Results In BOND-003 Trial [Yahoo! Finance]
Low
Report
CG Oncology (CGON) Reports Promising Results In BOND-003 Trial [Yahoo! Finance]
9/8
12:38 pm
cgon
CG Oncology (NASDAQ:CGON) is now covered by analysts at Jones Trading. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
CG Oncology (NASDAQ:CGON) is now covered by analysts at Jones Trading. They set a "buy" rating and a $50.00 price target on the stock.